Year 2023 / Volume 115 / Number 11
Letter
Immune checkpoint inhibitor-mediated colitis in a patient with epidermoid metastatic lung cancer: new and emerging toxicities

663

DOI: 10.17235/reed.2023.9813/2023

Marta Álvarez-García, Lola Otegui, Sergio Farrais Villalba, Juan Carlos Porres Cubero,

Abstract
In recent years, the development of immunotherapy has been stablished with monoclonals antibodies against control immune molecules in T lymphocytes, tumor cells and other cells, which block lymphocyte activation and suppress immune response. These molecules are Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death-ligand 1 (PD-1). Despite clinical benefits, these therapies are not exempt from side effects known as immune-related adverse events (irAEs). We report the case of a 68-year-old female with stage IIIB epidermoid lung cancer diagnosed in 2017.
New comment
Comments
No comments for this article
References
1. Céspedes Martínez E, Robles Alonso V, Herrera-De Guise C, Mayorga L, Casellas F, Roca-Herrera M, Borruel N. Severe and refractory gastrointestinal toxicity due to immune checkpoint inhibitors: clinical experience in a tertiary referral hospital. Rev Esp Enferm Dig. 2023 May 12. doi: 10.17235/reed.2023.9436/2022. Epub ahead of print. PMID: 37170542.
DOI: 10.17235/reed.2023.9436/2022. Epub ahead of print. PMID: 37170542
2. Hashash JG, Francis FF, Farraye FA. Diagnosis and Management of Immune Checkpoint Inhibitor Colitis. Gastroenterol Hepatol. agosto de 2021;17(8):358-66.
3. Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology. marzo de 2021;160(4):1384-93.
4. Fernández-Gordón Sánchez FM, Gómez-Domínguez E, Paredes Ruiz D, Rodríguez Gil Y, Martín Algíbez A, Fernández Vázquez I, Martínez Montiel P. Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury. Rev Esp Enferm Dig. 2022;114:356-357.
DOI: 10.17235/reed.2022.8618/2022
5. Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O, et al. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol. julio de 2020;5(7):679-97.
Related articles

Original

Assessing inflammatory bowel disease monitoring procedures in Spain: insights from the IBD-PODCAST study

DOI: 10.17235/reed.2025.11190/2025

Letter

Broadening perspectives in the treatment of chronic pouchitis

DOI: 10.17235/reed.2024.10865/2024

Letter

Association of various symptoms and histological alterations in the diagnosis of pediatric ulcerative colitis

DOI: 10.17235/reed.2024.10834/2024

Letter

Association between ulcerative colitis and acute appendicitis - A Mendelian randomization study

DOI: 10.17235/reed.2024.10818/2024

Letter

Ulcerative colitis complicating pneumomediastinum, subcutaneous emphysema and pneumothorax

DOI: 10.17235/reed.2024.10795/2024

Letter

Refractory gastroduodenal ulcers: investigating non-peptic etiologies

DOI: 10.17235/reed.2024.10782/2024

Letter

Correlation of endoscopic findings with histological alterations in pediatric ulcerative colitis

DOI: 10.17235/reed.2024.10755/2024

Original

Analysis of the effectiveness and safety of maintenance treatment with intravenous ustekinumab in inflammatory bowel disease

DOI: 10.17235/reed.2024.10731/2024

Letter

Mycofenolate-induced ileocolitis

DOI: 10.17235/reed.2024.10713/2024

Letter

Lamotrigine induced drug reaction with eosinophilia and systemic symptoms (DRESS) presenting with eosinophilic pan-colitis, cholestasis and cytomegalovirus reactivation

DOI: 10.17235/reed.2024.10681/2024

Letter

An uncommon cause of ascites - Eosinophilic enterocolitis with serous involvement

DOI: 10.17235/reed.2024.10665/2024

Letter

Eosinophilic colitis with favorable response to vedolizumab

DOI: 10.17235/reed.2024.10660/2024

Letter

A case of exuberant endoscopic presentation of asymptomatic eosinophilic colitis

DOI: 10.17235/reed.2024.10577/2024

Letter

Management of cytomegalovirus reactivation in a patient with immunotherapy-induced gastritis

DOI: 10.17235/reed.2024.10550/2024

Letter

Ulcerative colitis complicated with hypermucinous dysplasia

DOI: 10.17235/reed.2024.10348/2024

Letter

Active microscopic colitis precipitated by fluoxetine

DOI: 10.17235/reed.2024.10336/2024

Letter

Diffuse colonic capillary hemangioma mimicking ulcerative colitis

DOI: 10.17235/reed.2024.10298/2024

Letter

Association of microscopic colitis and enteropathy due to olmesartan

DOI: 10.17235/reed.2024.10258/2024

Special Article

Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU

DOI: 10.17235/reed.2024.10250/2024

Letter

Immuno-mediated colitis induced by nivolumab that mimics endoscopically and histologically an ulcerative colitis

DOI: 10.17235/reed.2024.10180/2023

Letter

Salmonella-associated acute pancreatitis in a patient with ulcerative colitis

DOI: 10.17235/reed.2024.10198/2023

Letter

An Epstein-Barr virus-positive mucocutaneous ulcer in a patient with ulcerative colitis: a recently described entity to take into account

DOI: 10.17235/reed.2024.10168/2023

Letter

Long-term remission achieved in a rare case of pyoderma gangrenosum and ulcerative colitis with surgery and postoperative infliximab

DOI: 10.17235/reed.2024.10144/2023

Letter

Ulcerative colitis induced by obinutuzumab in a patient treated for a follicular lymphoma

DOI: 10.17235/reed.2023.10009/2023

Letter

Effectiveness of 4 L, 2 L, and 1 L polyethylene glycol (PEG) bowel preparation for colonoscopy in patients with ulcerative colitis: a retrospective study

DOI: 10.17235/reed.2023.9979/2023

Original

Psychological disorders and coping strategies in patients with inflammatory bowel disease. Their impact on health-related quality of life

DOI: 10.17235/reed.2023.9935/2023

Review

Virtual chromoendoscopy for the identification of colonic dysplasia in patients with inflammatory bowel disease. A systematic review

DOI: 10.17235/reed.2025.9878/2023

Letter

Is cervical dysplasia a major concern in females with inflammatory bowel disease? A Spanish retrospective study

DOI: 10.17235/reed.2023.9890/2023

Editorial

Safe use of proton-pump inhibitors

DOI: 10.17235/reed.2023.9834/2023

Letter

Tofacitinib-induced eosinophilia

DOI: 10.17235/reed.2023.9831/2023

Letter

Treatment of steroid-refractory immune checkpoint inhibitor-induced intestinal pseudo-obstruction with infliximab

DOI: 10.17235/reed.2023.9796/2023

Original

Ulcerative colitis overall disease severity index predicts colectomy: a prospective cohort study

DOI: 10.17235/reed.2023.9754/2023

Letter

Infliximab-induced psoriasis in an ulcerative colitis patient successfully treated with guselkumab

DOI: 10.17235/reed.2023.9745/2023

Original

Development and validation of a nomogram to predict non-response to 5-aminosalicylic acid in patients with ulcerative colitis

DOI: 10.17235/reed.2023.9703/2023

Letter

Idiopathic mesenteric phlebosclerotic colitis associated with Chinese herbal medicine

DOI: 10.17235/reed.2023.9641/2023

Letter

Extensive involvement of indolent T-cell lymphoma in a patient with ulcerative colitis

DOI: 10.17235/reed.2023.9623/2023

Letter

Iatrogenic rectal perforation due to application of topical treatment in a patient with ulcerative colitis: a rare complication

DOI: 10.17235/reed.2023.9599/2023

Original

Long-term clinical outcomes after the discontinuation of anti-TNF agents in patients with inflammatory bowel disease: a meta-analysis

DOI: 10.17235/reed.2023.9537/2023

Letter

Severe outbreak of ulcerative colitis and cerebral neoplasia. Difficult management in COVID time

DOI: 10.17235/reed.2023.9527/2023

Letter

Lymphocytic colitis with macroscopic findings

DOI: 10.17235/reed.2023.9497/2023

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Review

Research progress in the combined treatment of ulcerative colitis

DOI: 10.17235/reed.2023.9444/2022

Original

Severe and refractory gastrointestinal toxicity due to immune checkpoint inhibitors: clinical experience in a tertiary referral hospital

DOI: 10.17235/reed.2023.9436/2022

Letter

Prediagnosis of soft tissue infection that was finally diagnosed as pyoderma gangrenosum of ulcerative colitis

DOI: 10.17235/reed.2022.9332/2022

Letter

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Original

Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis

DOI: 10.17235/reed.2022.9228/2022

Letter

A rare case of ulcerative colitis following Bacillus Calmette-Guérin therapy

DOI: 10.17235/reed.2022.9191/2022

Letter

Ulcerative colitis complicated by autoimmune hepatitis-primary biliary cholangitis-primary sclerosing cholangitis overlap syndrome

DOI: 10.17235/reed.2022.9183/2022

Letter

Chinese dragon sign of ulcerative colitis

DOI: 10.17235/reed.2022.9154/2022

Letter

Pyoderma gangrenosum in ulcerative colitis - An exuberant and painful complication

DOI: 10.17235/reed.2022.9120/2022

Original

The volume of ERCP per endoscopist is associated with a higher technical success and a lower post-ERCP pancreatitis rate. A prospective analysis

DOI: 10.17235/reed.2022.9056/2022

Letter

Ulcerative colitis exacerbated by strongyloidiasis

DOI: 10.17235/reed.2022.9044/2022

Letter

The neutrophil-lymphocyte ratio as a predictor of steroid response in patients with severe ulcerative colitis: a retrospective cohort study

DOI: 10.17235/reed.2022.9006/2022

Editorial

Drug induced liver injury by immunotherapy

DOI: 10.17235/reed.2022.9179/2022

Letter

Colitis cystica profunda of the rectum diagnosed by endoscopic submucosal dissection

DOI: 10.17235/reed.2022.8994/2022

Letter

Dual biologic therapy for severe ulcerative colitis, concomitant extraintestinal manifestations and an orbital osteoma: a successful treatment

DOI: 10.17235/reed.2022.8964/2022

Letter

A rare case of an intestinal ulcer: AIDS and amebic colitis in a homosexual man with ulcerative colitis

DOI: 10.17235/reed.2022.8903/2022

Letter

Upadacitinib in refractory ulcerative colitis

DOI: 10.17235/reed.2022.8870/2022

Letter

One appendix too many: a severe IBD-U case in remission after appendectomy

DOI: 10.17235/reed.2022.8809/2022

Letter

Intestinal disease secondary to tocilizumab

DOI: 10.17235/reed.2022.8818/2022

Original

Health-related quality of life decline in clinically stable inflammatory bowel disease patients during the COVID-19 outbreak

DOI: 10.17235/reed.2022.8668/2022

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury

DOI: 10.17235/reed.2022.8618/2022

Digestive Diseases Image

Immune-mediated colitis secondary to treatment with nivolumab-ipilimumab in a patient with stage IV kidney cancer: what do we do when corticosteroids fail?

DOI: 10.17235/reed.2022.8632/2022

Letter

NSAID-induced ischemic colitis

DOI: 10.17235/reed.2022.8605/2022

Letter

Cytomegalovirus associated rectal ulcer as a manifestation of primary HIV infection

DOI: 10.17235/reed.2022.8546/2021

Letter

Mesalazine induced interstitial pneumonitis in the COVID era

DOI: 10.17235/reed.2022.8635/2021

Original

Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia

DOI: 10.17235/reed.2022.8380/2021

Letter

Effect of symbiotic fermented milk together with conventional therapy in the eradication treatment of Helicobacter pylori

DOI: 10.17235/reed.2021.8302/2021

Letter

Acute neutrophilic gastritis induced by nivolumab used as treatment for non- metastatic malignant melanoma

DOI: 10.17235/reed.2021.8295/2021

Review

Adherence improvement in patients with ulcerative colitis: a multidisciplinary consensus document

DOI: 10.17235/reed.2021.8130/2021

Digestive Diseases Image

Portal pneumatosis in a patient with severe Salmonella colitis

DOI: 10.17235/reed.2021.8090/2021

Letter

Abdominal metastatic melanoma invading the transverse colon and stomach

DOI: 10.17235/reed.2021.8052/2021

Letter

Leflunomide as a cause of collagenous colitis: an entity to consider

DOI: 10.17235/reed.2021.8015/2021

Original

Incidence of inflammatory bowel disease and phenotype at diagnosis in 2011: results of the Epi-IBD 2011 study in the Vigo area

DOI: 10.17235/reed.2021.8003/2021

Letter

Tofacitinib, a useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient

DOI: 10.17235/reed.2021.7977/2021

Review

Risk factors and management strategies associated with non-response to aminosalicylates as a maintenance treatment in ulcerative colitis

DOI: 10.17235/reed.2021.7797/2021

Letter

Influence of the onset of the SARS-CoV-2 pandemic on the diagnosis and treatment of ulcerative colitis

DOI: 10.17235/reed.2021.7768/2020

Original

Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study

DOI: 10.17235/reed.2021.7683/2020

Original

Thiopurine adherence: a high prevalence with low impact on UC outcomes

DOI: 10.17235/reed.2021.7630/2020

Letter

A case of severe diverticulosis in a patient with ulcerative colitis

DOI: 10.17235/reed.2020.7529/2020

Review

The use of contrast-enhanced ultrasound for chronic inflammatory bowel disease

DOI: 10.17235/reed.2020.7499/2020

Original

Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results

DOI: 10.17235/reed.2020.7472/2020

Digestive Diseases Image

Phlebosclerotic colitis: an unusual cause of abdominal pain and hematochezia

DOI: 10.17235/reed.2020.7358/2020

Letter

Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19

DOI: 10.17235/reed.2020.7297/2020

Original

Prevalence and factors associated with poor sleep quality in inflammatory bowel disease outpatients

DOI: 10.17235/reed.2020.7202/2020

Letter

Author´s answer to: “Effect of adacolumn® in ulcerative colitis with COVID-19”

DOI: 10.17235/reed.2020.7188/2020

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Rapid reviews

COVID-19, coronavirus, SARS-CoV-2 and the small bowel

DOI: 10.17235/reed.2020.7137/2020

Letter

Eosinophilic enterocolitis: an uncommon cause of chronic diarrhea

DOI: 10.17235/reed.2020.7071/2020

Review

Vitamin D and inflammatory bowel disease: what do we know so far?

DOI: 10.17235/reed.2020.7061/2020

Original

Glasgow prognostic score is a predictive index for postoperative infectious complications after total proctocolectomy in ulcerative colitis patients

DOI: 10.17235/reed.2020.7047/2020

Letter

Sweet syndrome in severe ulcerative flare

DOI: 10.17235/reed.2020.6995/2020

Original

Autoimmune sequential overlap syndrome (autoimmune hepatitis/primary sclerosing cholangitis) and inflammatory bowel disease: three clinical cases

DOI: 10.17235/reed.2020.6938/2020

Letter

Retrograde enteroclysis by double balloon enteroscopy in a patient with blunt abdominal trauma: small bowel stricture, intraluminal vascular lesion and Crohn’s disease

DOI: 10.17235/reed.2020.6891/2020

Letter

Severe enterocolitis secondary to ipilimumab and nivolumab with an excellent response to a single dose of infliximab

DOI: 10.17235/reed.2020.6886/2020

Original

Meta-analysis of protein intake on the effect of Crohn’s disease and ulcerative colitis

DOI: 10.17235/reed.2020.6851/2019

Original

Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn’s disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain

DOI: 10.17235/reed.2020.6847/2019

Original

Index of the Mayo Endoscopy and Ulcerative Colitis Endoscopy Index of Severity: are they equally valid?

DOI: 10.17235/reed.2020.6832/2019

Letter

Dasatinib-induced colitis: discovering the side effects of immunotherapy

DOI: 10.17235/reed.2020.6789/2019

Original

Predictive factors of clinical response to treatment with anti-TNF agents in ulcerative colitis: what have we learned from our patients?

DOI: 10.17235/reed.2020.6688/2019

Original

Association between autoimmune pancreatitis and ulcerative colitis: a report of 12 patients

DOI: 10.17235/reed.2020.6677/2019

Review

Treatment of microscopic colitis: the role of budesonide and new alternatives for refractory patients

DOI: 10.17235/reed.2019.6655/2019

Letter

Intra-abdominal desmoid tumor and chronic inflammatory bowel disease. An uncommon scenario

DOI: 10.17235/reed.2020.6648/2019

Original

Diet as an environmental trigger in inflammatory bowel disease: a retrospective comparative study in two European cohorts

DOI: 10.17235/reed.2020.6552/2019

Review

Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis

DOI: 10.17235/reed.2019.6336/2019

Original

Development and validation of the QUECOMIICAT questionnaire: a tool to assess disease-related knowledge in patients with inflammatory bowel disease

DOI: 10.17235/reed.2019.6298/2019

Original

Differences in the need for adalimumab dose optimization between Crohn’s disease and ulcerative colitis

DOI: 10.17235/reed.2019.6148/2018

Letter

The first reported case of colonic infection caused by Candida glabrata

DOI: 10.17235/reed.2019.6057/2018

Case Report

Leukocytoclastic vasculitis after vaccination in a patient with inflammatory bowel disease

DOI: 10.17235/reed.2019.5963/2018

Letter

The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?

DOI: 10.17235/reed.2019.5841/2018

Original

Vitamin D deficiency in outpatients with inflammatory bowel disease: prevalence and association with clinical-biological activity

DOI: 10.17235/reed.2018.5714/2018

Original

The association between de novo inflammatory bowel disease and celiac disease

DOI: 10.17235/reed.2019.5535/2018

Original

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months

DOI: 10.17235/reed.2018.5368/2017

Case Report

Magnesium poisoning, multi-organ failure and ischemic colitis secondary to chronic ingestion of a parapharmacy product

DOI: 10.17235/reed.2018.5355/2017

Original

Using the internet to evaluate the opinion of patients with inflammatory bowel disease with regard to the available information

DOI: 10.17235/reed.2018.5331/2017

Case Report

Serrated polyposis syndrome associated with long-standing inflammatory bowel disease

DOI: 10.17235/reed.2017.5068/2017

Digestive Diseases Image

Immune mediated colitis caused by lung cancer treatment with atezolizumab

DOI: 10.17235/reed.2017.5060/2017

Case Report

Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis

DOI: 10.17235/reed.2017.5024/2017

Letter to the Editor

Cytomegalovirus: associated ischemic colitis in an immunocompetent patient

DOI: 10.17235/reed.2017.4937/2017

Letter to the Editor

Fecal transplantation as a treatment for Clostridium difficile infection in patients with ulcerative colitis

DOI: 10.17235/reed.2017.4941/2017

Original

Medium to long-term efficacy and safety of oral tacrolimus in moderate to severe steroid refractory ulcerative colitis

DOI: 10.17235/reed.2017.4899/2017

Case Report

Fecal microbiota transplantation in recurrent Clostridium difficile infection in a patient with concomitant inflammatory bowel disease

DOI: 10.17235/reed.2017.4819/2016

Original

Knowledge of disease and access to a specialist reported by Spanish patients with ulcerative colitis. UC-LIFE survey

DOI: 10.17235/reed.2017.4748/2016

Letter to the Editor

Ulcerative colitis with gastric and duodenal involvement

DOI: 10.17235/reed.2017.4685/2016

Original

What is the real-life maintenance mesalazine dose in ulcerative colitis?

DOI: 10.17235/reed.2016.4620/2016

Original

The concerns of Spanish patients with inflammatory bowel disease as measured by the RFIPC questionnaire

DOI: 10.17235/reed.2017.4621/2016

Letter to the Editor

Author´s reply to the letter: In response to the editorial “Sedation in endoscopy in 2016: Is it safe sedation with propofol led by the endoscopist in complex situations?”

DOI: 10.17235/reed.2016.4611/2016

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Original

The use of a segmental endoscopic score may improve the prediction of clinical outcomes in acute severe ulcerative colitis

DOI: 10.17235/reed.2016.4470/2016

Letter to the Editor

In response to the editorial “Sedation in endoscopy in 2016: Is it safe sedation with propofol led by the endoscopist in complex situations?”

DOI: 10.17235/reed.2016.4471/2016

Special Article

Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva

DOI: 10.17235/reed.2016.4232/2016

Original

Meta-analysis of the association between appendiceal orifice inflammation and appendectomy and ulcerative colitis

DOI: 10.17235/reed.2016.4176/2015

Letter to the Editor

Ischemic colitis in an athlete: running is not always good for you

DOI: 10.17235/reed.2016.4184/2015

Digestive Diseases Image

All that glitters is not gold. A different cause for an "ulcerative colitis"

Letter to the Editor

Ulcerative colitis in a patient with common variable immunodeficiency: does the treatment differ from the routine?

DOI: 10.17235/reed.2016.4115/2015

Original

Initial experience with golimumab in clinical practice for ulcerative colitis

DOI: 10.17235/reed.2016.4068/2015

Original

Endoluminal calprotectin measurement in assessment of pouchitis and a new index of disease activity: a pilot study

DOI: 10.17235/reed.2016.4066/2015

Case Report

Segmental colitis caused by idiopathic myointimal hyperplasia of mesenteric veins

DOI: 10.17235/reed.2016.4051/2015

Case Report

Mesalamine-induced myopericarditis - A case report

DOI: 10.17235/reed.2016.4016/2015

Digestive Diseases Image

Fatal Campylobacter jejuni ileocolitis

Case Report

Severe ischemic colitis following olanzapine use - A case report

DOI: 10.17235/reed.2016.3944/2015

Editorial

INTENSIFICATION OF MAINTENANCE THERAPY WITH INFLIXIMAB IN ULCERATIVE COLITIS

DOI: 10.17235/reed.2015.3907/2015

Digestive Diseases Image

Nodular colitis: endoscopic image an unusual finding

Case Report

Olanzapine-induced ischemic colitis

DOI: 10.17235/reed.2015.3856/2015

Original

FREQUENCY, PREDICTORS, AND CONSEQUENCES OF MAINTENANCE INFLIXIMAB THERAPY INTENSIFICATION IN ULCERATIVE COLITIS

DOI: 10.17235/reed.2015.3804/2015

Original

Impact of the age of diagnosis on the natural history of ulcerative colitis

DOI: 10.17235/reed.2015.3736/2015

Citation tools
Álvarez-García M, Otegui L, Farrais Villalba S, Porres Cubero J. Immune checkpoint inhibitor-mediated colitis in a patient with epidermoid metastatic lung cancer: new and emerging toxicities. 9813/2023


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 5817 visits.
This article has been downloaded 89 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 02/07/2023

Accepted: 13/07/2023

Online First: 04/08/2023

Published: 13/11/2023

Article Online First time: 33 days

Article editing time: 134 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Home
Articles
Current issues
Previous issues
Most read articles
Clinical guidelines
Reviews
Topic collection
Submit a manuscript
Submit a manuscript
Information for authors
Language editing services
Editorial time – Publication time
ORCID guide
PubMed guide
Journal info
About the journal
Editorial board
For reviewers
For advertisers
REED centenary
Open access
Articles in press
REED awards
Home
Articles
Current issues
Previous issues
Most read articles
Clinical guidelines
Reviews
Topic collection
Submit a manuscript
Submit a manuscript
Information for authors
Language editing services
Editorial time – Publication time
ORCID guide
PubMed guide
Journal info
About the journal
Editorial board
For reviewers
For advertisers
REED centenary
Open access
Articles in press
REED awards
Home
Articles
Current issues
Previous issues
Most read articles
Clinical guidelines
Reviews
Topic collection
Submit a manuscript
Submit a manuscript
Information for authors
Language editing services
Editorial time – Publication time
ORCID guide
PubMed guide
Journal info
About the journal
Editorial board
For reviewers
For advertisers
REED centenary
Open access
Articles in press
REED awards
Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2025 y Creative Commons. The Spanish Journal of Gastroenterology